Healthcare provider profile · identity verified

Rahat Taswir, MD

Psychiatry · YORK, PA · NPI 1073576278

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Clonazepam	Clonazepam	644	83
Quetiapine Fumarate	Quetiapine Fumarate	638	70
Lamotrigine	Lamotrigine	607	92
Trazodone Hcl	Trazodone Hcl	607	100
Duloxetine Hcl	Duloxetine Hcl	552	73
Risperidone	Risperidone	436	50
Alprazolam	Alprazolam	398	52
Lorazepam	Lorazepam	394	58
Fluoxetine Hcl	Fluoxetine Hcl	339	37
Sertraline Hcl	Sertraline Hcl	337	50
Olanzapine	Olanzapine	332	40
Escitalopram Oxalate	Escitalopram Oxalate	318	45
Benztropine Mesylate	Benztropine Mesylate	317	49
Buspirone Hcl	Buspirone Hcl	305	45
Hydroxyzine Pamoate	Hydroxyzine Pamoate	284	56
Venlafaxine Hcl Er	Venlafaxine Hcl	262	34
Hydroxyzine Hcl	Hydroxyzine Hcl	260	51
Aripiprazole	Aripiprazole	234	45
Bupropion Hcl Sr	Bupropion Hcl	227	34
Citalopram Hbr	Citalopram Hydrobromide	221	26
Doxepin Hcl	Doxepin Hcl	221	27
Lurasidone Hcl	Lurasidone Hcl	207	25
Mirtazapine	Mirtazapine	194	22
Zolpidem Tartrate	Zolpidem Tartrate	182	28
Ziprasidone Hcl	Ziprasidone Hcl	167	23
Divalproex Sodium	Divalproex Sodium	163	17
Clozapine	Clozapine	155	13
Haloperidol	Haloperidol	153	20
Paroxetine Hcl	Paroxetine Hcl	151	25
Bupropion Xl	Bupropion Hcl	128	17
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	123	15
Gabapentin	Gabapentin	123	15
Prazosin Hcl	Prazosin Hcl	119	18
Diazepam	Diazepam	112	16
Oxcarbazepine	Oxcarbazepine	93	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	88	18
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	82	11
Fluvoxamine Maleate	Fluvoxamine Maleate	79	suppressed
Latuda	Lurasidone Hcl	77	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	68	suppressed
Lithium Carbonate	Lithium Carbonate	68	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	60	suppressed
Clomipramine Hcl	Clomipramine Hcl	59	suppressed
Lithium Carbonate Er	Lithium Carbonate	54	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	52	suppressed
Ingrezza	Valbenazine Tosylate	51	suppressed
Trintellix	Vortioxetine Hydrobromide	49	suppressed
Vilazodone Hcl	Vilazodone Hcl	44	suppressed
Vraylar	Cariprazine Hcl	43	suppressed
Donepezil Hcl	Donepezil Hcl	39	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	39	suppressed
Propranolol Hcl	Propranolol Hcl	39	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	37	suppressed
Perphenazine	Perphenazine	33	suppressed
Divalproex Sodium Er	Divalproex Sodium	30	suppressed
Temazepam	Temazepam	30	suppressed
Topiramate	Topiramate	29	suppressed
Abilify Maintena	Aripiprazole	28	suppressed
Carbamazepine	Carbamazepine	28	suppressed
Aristada	Aripiprazole Lauroxil	27	suppressed
Bupropion Hcl	Bupropion Hcl	26	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Methylphenidate Er	Methylphenidate Hcl	25	suppressed
Rexulti	Brexpiprazole	25	suppressed
Invega Sustenna	Paliperidone Palmitate	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Caplyta	Lumateperone Tosylate	21	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	20	suppressed
Zaleplon	Zaleplon	17	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	15	suppressed
Fluphenazine Decanoate	Fluphenazine Decanoate	14	suppressed
Belsomra	Suvorexant	13	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	13	suppressed
Loxapine	Loxapine Succinate	13	suppressed
Ramelteon	Ramelteon	13	suppressed
Saphris	Asenapine Maleate	13	suppressed
Trifluoperazine Hcl	Trifluoperazine Hcl	13	suppressed
Guanfacine Hcl	Guanfacine Hcl	12	suppressed
Guanfacine Hcl Er	Guanfacine Hcl	12	suppressed
Ambien	Zolpidem Tartrate	11	suppressed
Lamictal	Lamotrigine	11	suppressed
Rivastigmine	Rivastigmine	11	suppressed
Xanax	Alprazolam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error